Bellevue Life Sciences Acquisition Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Peter Hwang

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	4.7yrs
CEO ownership	n/a
Management average tenure	no data
Board average tenure	1.8yrs

Recent management updates

Recent updates

CEO

Peter Hwang (48 yo)

4.7yrs

Tenure

Mr. Kuk Hyoun Hwang, also known as Peter, is Chief Executive Officer and Director of Bellevue Life Sciences Acquisition Corp. since March 2020 and serves as its Executive Chairman. Mr. Hwang is the Managin...

Board Members

Name	Position	Tenure	Compensation	Ownership
Kuk Hwang	CEO & Executive Chairman	4.7yrs	no data	no data
Jun Whang	Director	4.3yrs	no data	no data
Jin Park	Independent Director	1.8yrs	no data	0.49% $ 225.2k
Geon Lee	Independent Director	less than a year	no data	no data
Sang Kim	Independent Director	less than a year	no data	no data

1.8yrs

Average Tenure

56yo

Average Age

Experienced Board: BLAC.U's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.

Bellevue Life Sciences Acquisition Management

Management criteria checks 0/4

Key information

Recent management updates

Bellevue Life Sciences Acquisition Corp., Annual General Meeting, Nov 12, 2024

Bellevue Life Sciences Acquisition Corp. Announces the Resignation of Hosun Euh as Member of the Board of Directors, Effective June 21, 2023

High number of new and inexperienced directors

Recent updates

Bellevue Life Sciences Acquisition Corp., Annual General Meeting, Nov 12, 2024

Nasdaq Hearings Panel Grants Bellevue Life Sciences Acquisition's Request for Continued Listing on the Nasdaq, Subject to Compliance with the Minimum Public Holders Requirement on or before February 17, 2025

Bellevue Life Sciences Acquisition Receives a Letter from Nasdaq Due to its No Longer Meets the Minimum 300 Public Holders Requirement for The Nasdaq Capital Market Pursuant to Nasdaq Listing Rule 5550(a)(3)

Bellevue Life Sciences Acquisition Corp. announced delayed 10-Q filing

Bellevue Life Sciences Acquisition Receives Non-Compliance Notice from Nasdaq

Bellevue Life Sciences Acquisition Corp. announced that it has received $0.14 million in funding

Nasdaq Grants Bellevue Life Sciences Acquisition an Extension of Time to Regain Compliance with the Minimum Public Holders Requirement

Bellevue Life Sciences Acquisition Corp. announced delayed annual 10-K filing

Bellevue Life Sciences Acquisition Receives Non-Compliance Letter from Nasdaq

Bellevue Life Sciences Acquisition Notifies the Listing Qualifications Department of Nasdaq Regarding the Company Is Not Currently in Compliance with Nasdaq Listing Rule 5605(c)(2)(A)